Harnessing nanotechnology for cardiovascular disease applications - a comprehensive review based on bibliometric analysis
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Artificial Intelligence in Healthcare and Education
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 201610.1016/S0140-6736(17)32154-2 ↗
2. WHO reveals leading causes of death and disability worldwide: 2000–2019〈https://www.who.int/news/item/09–12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000–2019〉, (Accessed 24 August 2021).
3. Bending the curve in cardiovascular disease mortality: bethesda + 40 and beyond10.1161/CIRCULATIONAHA.120.046501 ↗
4. WHO list of priority medical devices for management of cardiovascular diseases and diabetes (WHO Medical device technical series), World Health Organization2021.
5. Cardiovascular diseases (CVDs). 〈https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)〉, (Accessed 24 August 2021).
6. Global Action Plan for the Prevention and Control of NCDs 2013–2020, 2013.
7. Biomimetic nanoparticle technology for cardiovascular disease detection and treatment10.1039/C9NH00291J ↗
8. Impact of high-sensitivity cardiac troponin on use of coronary angiography, cardiac stress testing, and time to discharge in suspected acute myocardial infarction10.1093/eurheartj/ehw232 ↗
9. V.L. Roger, Cardiovascular diseases in populations: secular trends and contemporary challenges-Geoffrey Rose lecture, European Society of Cardiology meeting 2014, Eur. Heart J. 36 (2015) 2142–2146.10.1093/eurheartj/ehv220 ↗
10. Mechanisms of cardiac regeneration10.1016/j.devcel.2016.01.018 ↗
11. A molecular imaging primer: modalities, imaging agents, and applications10.1152/physrev.00049.2010 ↗
12. Superparamagnetic iron oxide nanoparticles for MR imaging and therapy: design considerations and clinical applications10.1016/j.coph.2014.08.002 ↗
13. Activatable magnetic resonance nanosensor as a potential imaging agent for detecting and discriminating thrombosis10.1039/C8NR05095C ↗
14. Gold-nanorod enhances dielectric voltammetry detection of c-reactive protein: a predictive strategy for cardiac failure10.1016/j.bios.2019.01.042 ↗
15. Tea phenols in bulk and nanoparticle form modify DNA damage in human lymphocytes from colon cancer patients and healthy individuals treated in vitro with platinum-based chemotherapeutic drugs10.2217/nnm.12.126 ↗
16. Nanotechnology in preclinical pharmacokinetics
17. Development of sustained release “Nanopolypill” of ischemic heart disease drugs – an experimental study10.2174/1573413710666140512221814 ↗
18. Application of the nano-drug delivery system in treatment of cardiovascular diseases10.3389/fbioe.2019.00489 ↗
19. Biomimetic nano drug delivery carriers for treating cardiovascular diseases
20. Carbon nanomaterials for cardiovascular theranostics: promises and challenges
21. Milestones and current achievements in development of multifunctional bioscaffolds for medical application
22. 3D electrospun nanofiber-based scaffolds: from preparations and properties to tissue regeneration applications10.1155/2021/8790143 ↗
23. Functional interaction between charged nanoparticles and cardiac tissue: a new paradigm for cardiac arrhythmia?10.2217/nnm.12.125 ↗
24. Nanomaterials for treating cardiovascular diseases: a review
25. Theranostic applications of nanomaterials in the field of cardiovascular diseases10.2174/1381612827666210701154305 ↗
26. Nanotechnology applications for cardiovascular disease treatment: Current and future perspectives
27. Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction. 〈https://clinicaltrials.gov/ct2/show/NCT01323296〉,(Accessed 24 August 2021).
28. IRon Nanoparticle Enhanced MRI in the Assessment of Myocardial infarctioN (IRNMAN). 〈https://clinicaltrials.gov/ct2/show/NCT01995799〉, (Accessed 24 August 2021).
29. A Safety Study of ABI-007 for In-Stent Restenosis. 〈https://clinicaltrials.gov/ct2/show/NCT00093223〉, (Accessed 24 August 2021).
30. Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis (SNAPIST-III). 〈https://clinicaltrials.gov/ct2/show/NCT00124943〉, (Accessed 24 August 2021).
31. Treatment of Patients With Atherosclerotic Disease With Methotrexate-associated to LDL Like Nanoparticles.〈https://clinicaltrials.gov/ct2/show/study/NCT04616872〉, (Accessed 24 August 2021).
32. Magnetic Nanoparticles System in Acute Coronary Syndrome. 〈https://clinicaltrials.gov/ct2/show/NCT02226523〉, (Accessed 24 August 2021).
33. Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like Nanoparticles (PAC-MAN). 〈https://clinicaltrials.gov/ct2/show/NCT04148833〉, (Accessed 24 August 2021).
34. The bibliometric analysis of scholarly production: how great is the impact?10.1007/s11192-015-1645-z ↗
35. Analysis of advanced healthcare materials: research trends of biomaterials in healthcare application10.1002/adhm.202002222 ↗
36. Research trend of nanoscience and nanotechnology - a bibliometric analysis of nano today10.1016/j.nantod.2021.101233 ↗
37. Do researchers know what the h-index is? And how do they estimate its importance?10.1007/s11192-021-03968-1 ↗
38. A bibliometric analysis: research progress and prospects on transition metal dichalcogenides in the biomedical field
39. Constructing bibliometric networks: a comparison between full and fractional counting10.1016/j.joi.2016.10.006 ↗
40. van Eck · 2014 · 285
41. Three new bibliometric indicators/approaches derived from keyword analysis10.1007/s11192-018-2768-9 ↗
42. Nanopharmaceuticals (part 1): products on the market10.2147/IJN.S46900 ↗
43. Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose-induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy10.2337/db13-1577 ↗
44. SIRT1 activation by curcumin pretreatment attenuates mitochondrial oxidative damage induced by myocardial ischemia reperfusion injury10.1016/j.freeradbiomed.2013.07.007 ↗
45. Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis via a PI3K/Akt/mTOR-dependent manner10.21037/cdt-19-707 ↗
46. Curcumin loaded mesoporous silica nanoparticles: assessment of bioavailability and cardioprotective effect10.1080/03639045.2019.1672717 ↗
47. Oskuee, The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial
48. Nitric oxide nano-delivery systems for cancer therapeutics: advances and challenges10.3390/antiox9090791 ↗
49. Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension10.1097/HJH.0000000000002429 ↗
50. Albumin nanoparticle formulation for heart-targeted drug delivery: in vivo assessment of congestive heart failure10.3390/ph14070697 ↗
51. Synthesis and characterization of peptide conjugated human serum albumin nanoparticles for targeted cardiac uptake and drug delivery10.1371/journal.pone.0254305 ↗
52. I. Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure, short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial10.1001/jama.287.12.1541 ↗
53. Novel milrinone nanoformulation for use in cardiovascular diseases: preparation and in vitro characterization10.1021/acs.molpharmaceut.7b00360 ↗
54. Targeting strategies for tissue-specific drug delivery10.1016/j.cell.2020.02.001 ↗
55. Nanomedicine10.1056/NEJMra0912273 ↗
56. Recent development of gene therapy for pancreatic cancer using non-viral nanovectors10.1039/D1BM00748C ↗
57. Mechanisms of drug release from advanced drug formulations such as polymeric-based drug-delivery systems and lipid nanoparticles10.1007/s40005-017-0320-1 ↗
58. Kinetic approach for the study of noncovalent interaction between [Ru(NH3)5pz]2+ and gold nanoparticles10.1021/jp073577c ↗
59. Photo-electro active nanocomposite silk hydrogel for spatiotemporal controlled release of chemotherapeutics: an in vivo approach toward suppressing solid tumor growth10.1021/acsami.0c02470 ↗
60. Smart nanostructures for cargo delivery: uncaging and activating by light10.1021/jacs.6b08313 ↗
61. pH-responsivechitosan/sulfobutyl ether-beta-cyclodextrin supramolecular nanoparticles for controlled release of sodium ferulate10.1002/pen.25479 ↗
62. Responsive disassembly of nucleic acid nanocomplex in cells for precision medicine10.1016/j.nantod.2021.101160 ↗
63. Shear force responsive and fixed-point separated system for targeted treatment of arterial thrombus10.1016/j.nantod.2021.101186 ↗
64. Biomimetic fibrin-targeted and H2O2-responsive nanocarriers for thrombus therapy10.1016/j.nantod.2020.100986 ↗
65. siRNA nanoparticles targeting CaMKIIgamma in lesional macrophages improve atherosclerotic plaque stability in mice10.1126/scitranslmed.aay1063 ↗
66. Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits10.1007/s10557-013-6488-3 ↗
67. Low-dose methotrexate for the prevention of atherosclerotic events10.1056/NEJMoa1809798 ↗
68. The diosgenin prodrug nanoparticles with pH-responsive as a drug delivery system uniquely prevents thrombosis without increased bleeding risk10.1016/j.nano.2017.12.019 ↗
69. Thrombolytic agents: nanocarriers in controlled release10.1002/smll.202001647 ↗
70. Photosensitive nanocarriers for specific delivery of cargo into cells10.1038/s41598-020-58865-z ↗
71. Comprehensive review on ultrasound-responsive theranostic nanomaterials: mechanisms, structures and medical applications10.3762/bjnano.12.64 ↗
72. A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases10.1016/j.biomaterials.2019.119605 ↗
73. Nanoparticles administered intrapericardially enhance payload myocardial distribution and retention10.1016/j.jconrel.2017.07.012 ↗
74. Clinical Performance of Nano Plus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. 〈https://clinicaltrials.gov/ct2/show/NCT02929030〉, (Accessed 24 August 2021).
75. One-year clinical results of the NANO registry: a multicenter, prospective all-comers registry study in patients receiving implantation of a polymer-free sirolimus-eluting stent
76. Drug delivery via nano-, micro and macroporous coronary stent surfaces10.1517/17425247.4.3.287 ↗
77. Recent advances in biological macromolecule based tissue-engineered composite scaffolds for cardiac tissue regeneration applications10.1016/j.ijbiomac.2020.08.054 ↗
78. Cardiac tissue engineering: state of the art10.1161/CIRCRESAHA.114.300522 ↗
79. Cardiac tissue engineering: current state-of-the-art materials, cells and tissue formation10.1590/s1679-45082018rb4538 ↗
80. Development of the human heart10.1002/ajmg.c.31778 ↗
81. Cardiac tissue engineering: state-of-the-art methods and outlook10.1186/s13036-019-0185-0 ↗
82. Cardiac tissue engineering on the nanoscale10.1021/acsbiomaterials.7b00913 ↗
83. Shattering barriers toward clinically meaningful MSC therapies10.1126/sciadv.aba6884 ↗
84. Endothelial dysfunction: clinical implications in cardiovascular disease and therapeutic approaches10.3346/jkms.2015.30.9.1213 ↗
85. Endothelial progenitor cells as shuttle of anticancer agents10.1089/hum.2016.066 ↗
86. Bimodal imaging-visible nanomedicine integrating CXCR4 and VEGFa genes directs synergistic reendothelialization of endothelial progenitor cells10.1002/advs.202001657 ↗
87. Next generation of heart regenerative therapies: progress and promise of cardiac tissue engineering10.1038/s41536-021-00140-4 ↗
88. Poly(epsilon-caprolactone)-carbon nanotube composite scaffolds for enhanced cardiac differentiation of human mesenchymal stem cells10.2217/nnm.12.204 ↗
89. Gold nanoparticle loaded hybrid nanofibers for cardiogenic differentiation of stem cells for infarcted myocardium regeneration10.1002/mabi.201300407 ↗
90. Efficient cardiomyocyte differentiation of induced pluripotent stem cells on PLGA nanofibers enriched by platelet‐rich plasma10.1002/pat.5164 ↗
91. The effect of pore size on cell adhesion in collagen-GAG scaffolds10.1016/j.biomaterials.2004.02.052 ↗
92. Integrin signaling and cell growth control10.1016/S0955-0674(98)80144-0 ↗
93. Layer-by-layer assembly of 3D tissue constructs with functionalized graphene10.1002/adfm.201401300 ↗
94. Nanowired three-dimensional cardiac patches10.1038/nnano.2011.160 ↗
95. Graphene oxide flakes as a cellular adhesive: prevention of reactive oxygen species mediated death of implanted cells for cardiac repair10.1021/nn507149w ↗
96. A PNIPAAm-based thermosensitive hydrogel containing SWCNTs for stem cell transplantation in myocardial repair10.1016/j.biomaterials.2014.03.067 ↗
97. Carbon-nanotube-embedded hydrogel sheets for engineering cardiac constructs and bioactuators10.1021/nn305559j ↗
98. Nanoscale cues regulate the structure and function of macroscopic cardiac tissue constructs10.1073/pnas.0906504107 ↗
99. Regulation of the microenvironment for cardiac tissue engineering10.2217/rme-2016-0132 ↗
100. Dynamic cell-cell and cell-ECM interactions in the heart10.1016/j.yjmcc.2013.10.006 ↗